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Summary A workshop of the Project on Evaluation of Screening Programmes of the International Union
against Cancer (UICC) was held in Lyon, France, on November 20-22, 1984. The focus of the workshop was
on screening for gynaecological cancer, especially for cancer of the cervix uteri. This report summarizes the
presentations, conclusions and recommendations from this workshop.
Screening for cervical cancer
Since the 1940s screening programmes for cervical
cancer have been introduced all over the world,
notably in North America, the United Kingdom
and the Nordic Countries. In spite of long
traditions and wide spread application, there has
been disagreement on the overall effectiveness of
the programmes and their most efficient and
effective organisational setting. This variation in
opinion has resulted in differences in organisational
approaches to screening programmes. Such
variability has made it possible to compare the
effectiveness of the programmes in different
settings, and to learn about the natural history of
preclinical cervical lesions, to a greater extent than
would have been the case if identical organisational
approaches had been used.
In some countries screening is a part of normal
gynaecological practice and women are encouraged
to have a regular smear taken once a year or
sometimes less frequently. There are also screening
programmes specifcally designed to be independent
within the health services.
The programmes also show wide variation in
mechanisms to encourage participation. Some of
them are based on spontaneous participation and
screenees are informed of the opportunities to have
the test through mass communications systems. In
some of the Nordic countries there are organized
screening programmes which are population based
and nationwide. Each women is individually invited
to participate according to a fixed schedule.
Sometimes the organisation is based on the national
population registry and it is computerised.
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Evaluation ofthe effectiveness ofscreening
The first results on the impact of screening
stemmed from North America. Essentially
evaluation was based on time trends and
geographical correlations. British Columbia had the
first large scale screening programme which
originated as a diagnostic programme from the late
1940s. Later similar programmes were extended
over other provinces within Canada. In the United
States of America intensified screening programmes
commenced in the 1950s in several areas of
relatively limited size, e.g., Toledo, Louisville,
Olmstead County, and then tended to spread across
the country. There are several limitations to the
interpretation of trends in incidence and mortality
especially when, as in North America, rates were
falling before screening was introduced. However, it
seems that most of these programmes were
associated with trends in rates consistent with an
effect of screening on incidence and mortality, and
in both Canada and the United States there was a
strong correlation of screening intensity with
reduction in mortality.
In the UK screening for cervical cancer also
became wide spread practice. The overall time
trends in mortality, however, show no substantial
effect of screening. Nevertheless, detailed analyses
of trends suggest that without screening there
would have occurred an increase in mortality and
that, in practice in the UK, screening has probably
resulted in about a 20-30 per cent reduction in the
risk of and mortality from cervical cancer.
The most striking changes in cervical cancer rates
subsequent to the introduction of mass screening
occurred in some of the Nordic countries where
rates were stable or increasing until the start of
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organised screening programmes. Nearly complete
coverage of the population by organised
programmes was achieved rapidly in Iceland,
Finland and Sweden, as well as in parts of
Denmark, and was soon followed by sharp falls in
both incidence and mortality from cancer of the
cervix. In Norway an organised programme was
not introduced nationally and the risk increased
until the late 1970s. In addition to the organised
programme with personal letters of invitation, there
was much intensive spontaneous screening in all of
the Nordic countries including Norway. Therefore,
it is likely that organisational aspects play a major
role in ensuring an important impact of any
screening programme.
Several other programmes in Central and Eastern
Europe also gave an indication of an effect. Apart
from the overall population based trends, some
record systems were designed to provide incidence
rates by attendance in the programme. Invariably,
those attending the programme had a lower risk
than the nonattenders. Many of the problems
associated with mass screening such as the low
attendance of those at high risk, are problems of
organisation. To ensure maximum benefit from a
mass screening programme, therefore, emphasis
must be placed on organisational aspects.
Aetiology and risk
For a long time it has been known that there are
preclinical lesions, some of which are likely to
progress to frankly invasive carcinoma. Preinvasive
lesions occur with higher frequency and at younger
ages than invasive disease.
Risk of cervical cancer is closely related to sexual
habits. Early sexual experience and multiple
partners are related to high risk of cervical cancer.
The epidemiological observations fit the hypothesis
of an infectious aetiologic agent. Herpes virus type
II and human papilloma virus are those most
intensively studied. The changes in sexual mores in
western countries favour an increase rather than a
decrease in cervical cancer and/or preinvasive
lesions. However, as yet there are no specific
markers of of high risk which are of diagnostic
value.
Even if identification of high risk individuals
were possible, this does not imply that lower risk
women should be denied screening. A considerable
proportion of cervical cancers is diagnosed among
women without any high risk epidemiological
indicators. There is increasing evidence that 'high
risk males' (who may have been infected with a
transmissable agent in the past) may be in part
responsible for increasing the risk of cervical cancer
in their sexual partners. Even if an infectious agent
is a necessary step in the development of cervical
cancer, it is not likely to be the only step and many
other factors (eg, smoking) may also contribute.
In several populations a recent increase of
cervical malignancy and of preinvasive lesions has
occurred, especially at young ages. The increase in
preinvasive lesions is difficult to quantify reliably,
however, as changes in diagnostic practices
(especially introduction of colposcopy) and in
terminology of precancerous lesions coincided with
the apparent increase in incidence in many
countries.
The frequent preinvasive lesions found at ages
less than 25 seem to have a low probability of rapid
transition to invasive disease. The objective of
screening for cervical cancer is to prevent invasive
disease and under the age of 30 invasive cervical
cancer is rare, just a few cases in a population of
several million. Thus, present evidence does not
support extending screening programmes to very
young ages. Information gained through research
settings is continuously needed for adjusting the
policy, if necessary.
Analysis ofnatural history andpotential impact of
screening:
Important for the optimal design of a screening
programme is knowledge on the sojourn time
distribution, the time spent in the preclinical phase
by lesions which become invasive. This distribution
determines the risk of cervical cancer by time since
the last negative smear. Programmes recommending
screening once a year assume short sojourn times to
be frequent, as compared to a policy with a five
year lag between re-screening. No direct obser-
vations have so far existed on this basic question.
The indirect evidence has been somewhat confusing:
programmes recommending annual screening have
often been less effective than programmes
recommending even 5 year intervals.
The results of a large collaborative study
coordinated by the International Agency for
Research on Cancer (IARC) were considered. The
study was based on ten screening programmes in
different parts of the developed world. The sojourn
time distributions were very similar. The risk of an
invasive cancer during the first 2 years directly after
a negative smear was low compared to the risk
before screening. The protection decreased
gradually but some protection was seen up to ten
years after the smear. After two or more negative
smears a ten-fold relative protection was seen which
lasted for the first three years of follow-up.
The results of this study can be applied to a
population of women instead of to individuals,
assuming a 100 per cent attendance rate. The
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between the ages of 20 and 64 years was computed.
The maximum achievable reduction in risk is
slightly over 90 per cent stemming from annual
screening starting at age 20. The resources are thus
assumed to be sufficient for 35 tests per woman.
The impact is roughly the same with 3 year
screening intervals. Starting at age 25 with 3 year
screening intervals will still give 90 per cent
protection. This policy requires only 13 tests during
a lifetime.
Other alternatives are less effective but as few as
8 lifetime tests if properly scheduled (screening
every 5 years starting at age 25) will still provide 82
per cent protection. Approximately 80 per cent
protection is provided if screening is started as late
as at age 35 and repeated every 3 years, resulting in
10 lifetime tests.
Several simulation models have shown similar
results. Simulation is always based on assumptions
on the natural history which may or may not be
correct. Direct epidemiologic data on the sojourn
time distribution is likely to be a more reliable
means to take into account the natural history of
cervical cancer in planning screening programmes.
However, in the absence of direct observations
simulation modelling is a valuable tool in deciding
on optimal policy.
Although a majority of preinvasive neoplastic
lesions would probably not progress to invasive
cancer if left untreated, it is not possible to
distinguish the progressive from the non-progressive
cases. Therefore all these cases must be treated and
the screening programme will only succeed if
arrangements for prompt referral and treatment can
be guaranteed. Moreover these women remain at
high risk even after treatment and must therefore
be kept under close surveillance.
Essential elements ofa screening programme
The evidence available thus suggests that the
biology of cervical cancer is reasonably similar in
the developed countries and major differences in
the impact of screening are due to organisation.
Even though effective programmes may have
different organisational designs, most of the
effective programmes have common elements, and
lack of some of these characteristics may explain
the failure of some programmes.
For screening to be effective, it should be
organised according to an agreed policy. Essential
elements of such a programme are:
the target population has been identified;
the individual women are identifiable;
measures are available to guarantee high
coverage and attendance such as a personal letter of
invitation;
there are adequate field facilities for taking the
smears and adequate laboratory facilities to
examine them;
there is an organised quality control programme
on taking of the smears and on interpreting them;
adequate facilities must exist for diagnosis and
for appropriate treatment of confirmed neoplastic
lesions;
there is a carefully designed and agreed referral
system, an agreed link between the woman, the
laboratory and the clinical facility for diagnosis of
an abnormal screening test, for management of any
abnormalities found and for providing information
about normal screening tests;
evaluation and monitoring of the total
programme is organised in terms of incidence and
mortality rates among those attending, among
those not attending, at the level of the total target
population. Quality control of the epidemiological
data should be established.
Screening in developing countries
Cancer of the cervix is a most important disease in
developing countries. Although data are few,
similar natural histories as in Western countries
seem to exist. Thus, organisational approaches as in
Western countries seem to apply, though they
should be tied into the existing health care system
and take account of limited resources. Initiating a
programme of taking of smears is often feasible
using the opportunities presented by maternal and
child health care. Attention, as in developed
countries, has to be paid to the organisation and
quality control of laboratories and ensuring
appropriate treatment is given. It is particularly
important in developing countries that unrealistic
and unnecessary schedules of screening (eg annually
or biennially) are not imposed. Projects evaluating
appropriate approaches to screening in developing
countries should be encouraged. Extending the
results of the IARC collaborative study on the
sojourn time distribution to the example of a
developing country, it seems likely that as few as 5
lifetime tests, if properly scheduled, would provide
about a two-third reduction in risk of cervical
cancer.
Conclusions on screeningfor cancer of the cervix
Screening for any disease consumes many resources.
Therefore for each population a screening policy
for cervical cancer should be carefully developed.
This should be based on the available financial and
human resources. Competing health and other
needs will also influence the policy. However, there
is no good evidence that variation in the rate of
progression of preinvasive lesions, or variation in672 M. HAKAMA et al.
the risk of preinvasive lesions among western
populations, warrant differences in screening
policies.
The present evidence suggests that the maximum
achievable protection from mass screening for
cervical cancer at ages 20 to 64 is about 90 per
cent. Three year intervals between re-screenings
provide practically the same protection as annual
tests. The maximum achievable protection is about
80 per cent if the interval is changed to five years.
The most cost effective use of resources is to
target screening at age groups at appreciable risk of
invasive disease. In most populations, at present,
beginning screening at age 25 seems to provide
close to maximal protection.
It seems desirable to re-screen at the same
frequency irrespective of age. If a new programme
is introduced, then to have the greatest immediate
effect, screening should aim at the age groups 35-
60.
It is especially important to develop appropriate
screening strategies for developing countries where
the incidence of cancer of the cervix remains high
and where the resources for disease prevention may
be limited.
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Cancer of the other female genital organs
Several tests are available for screening for
endometrial cancer and ovarian cancer. Tests for
endometrial cancer based on cell sampling are
technically demanding. Although occult cancers are
diagnosed, their biological significance has not yet
been determined. Tests for ovarian cancer are under
development based on real time ultrasound and on
monoclonal antibodies. Mortality from ovarian
cancer now exceeds mortality from uterine cancer
in many countries, and further development of such
tests is to be encouraged. However, there is not
sufficient evidence yet available to determine
whether mass screening for endometrial cancer or
ovarian cancer will have an effect in reducing
mortality from the disease. Therefore they are not
currently recommended as a routine public health
policy.
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